Subscribe
Earnings
2 min read

Nestlé Petcare organic growth hits 5.3% as cat leads

Nestlé said on October 22nd, 2026 that Petcare organic growth was 5.3% in the third quarter, with 4.3% from real internal growth. Cat led, dog stayed soft, and the fourth quarter comparison gets harder.

Published on
October 23, 2026
Nestlé Petcare organic growth hits 5.3% as cat leads

Nestlé's Petcare organic growth hit 5.3% in the third quarter, nearly double the 2.8% of the second, and cat led it. The company reported the figures on October 22nd, 2026, with real internal growth (RIG), which strips out price, supplying 4.3 points.

Over nine months, Petcare organic growth stands at 3.5%. Reported nine month sales were flat at CHF 13.6B in both years, and organic growth leaves currency out.

Volume and mix, not price, carried the quarter

Nestlé's Petcare figures, with pricing as the gap between organic growth and RIG:

  • Third quarter: 5.3% organic growth, 4.3% RIG, 1.0% pricing
  • Second quarter: 2.8% organic growth, 2.0% RIG, 0.8% pricing
  • Nine months: 3.5% organic growth, 2.6% RIG, 0.9% pricing

The second quarter figures come from Nestlé's half year report, and we covered that period earlier. Pricing barely moved, so the acceleration is almost all volume and mix. By our math, RIG was 81% of third quarter organic growth, up from 71% in the second.

Cat and a cleaner pipeline explain the jump

Nestlé credits "continued strong performance in cat," with shipments to retailers matching strong sales off the shelf. Pro Plan and ONE, its largest brands, "continued to deliver strong sales growth." In Europe, wet cat food is "the main growth engine," Felix and Pro Plan grew at a double digit rate, and Petcare "continued to perform very strongly in e-commerce."

In Zone Americas, Petcare, 30% of the zone's sales, posted mid single digit organic growth led by RIG, with the US at mid single digit RIG.

That follows a second quarter that Nestlé said was held back by retailer inventory reduction in the US, even as sell out strengthened. If we had to guess, part of the third quarter jump is that comparison easing.

Dog is the other half of the picture. Nestlé says it "remained soft, partly reflecting the impact of warmer weather on consumption." Therapeutics growth accelerated, and Europe posted double digit organic growth in therapeutics and supplements.

The fourth quarter comparison gets harder

The same Nestlé note flags the next hurdle. The fourth quarter comparison for Petcare is higher because customers bought ahead of a price increase a year ago.

Group guidance, per the nine month release, is organic growth of 3% to 4% for 2026. Petcare's 3.5% over nine months is a segment figure, so the two are not a like for like check.

For rivals, the read is where the volume came from: cat, the flagship brands and online sales in Europe, while dog sat soft.

Cat is doing the work.

Source: Nestlé

Subscribe to newsletter

Join our newsletter to stay up to date on features and releases.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

By clicking Sign Up you're confirming that you agree with our Terms and Conditions.

What's Happening

Other News

More stories shaping the pet industry this week. From funding rounds and product launches to regulatory shifts and retail strategy, stay ahead of what's driving the market.

Read article
Tractor Supply comps turn positive as Petsense falls to 135 stores
Earnings
3 min read

Tractor Supply comps turn positive as Petsense falls to 135 stores

Tractor Supply's third-quarter comparable sales rose 0.4% after a 1.5% decline in the second, and the company said companion animal still runs below its average. It closed 74 Petsense stores and ended the quarter with 135.

Read article
Read article
Vimian agrees to buy a U.S. soft tissue surgery maker
Funding & M&A
2 min read

Vimian agrees to buy a U.S. soft tissue surgery maker

Vimian agreed on October 21st, 2026 to acquire Norfolk Medical Products, a U.S. maker of soft tissue surgery implants sold to veterinary clinics. The price was not stated, and completion is expected on or around November 2nd.

Read article
Read article
Warhound raises $200M to clone and gene-edit military dogs
Funding & M&A
3 min read

Warhound raises $200M to clone and gene-edit military dogs

Warhound emerged from stealth on October 22nd, 2026 with a $200M seed round to clone and gene-edit military working dogs using genetics licensed from Colossal Biosciences. Warhound says more than 80% of U.S. military working dogs come from Europe and less than half of those procured are fit for service.

Read article
View all articles